ZA201802496B - Jak kinase inhibitor compounds for treatment of respiratory disease - Google Patents
Jak kinase inhibitor compounds for treatment of respiratory diseaseInfo
- Publication number
- ZA201802496B ZA201802496B ZA2018/02496A ZA201802496A ZA201802496B ZA 201802496 B ZA201802496 B ZA 201802496B ZA 2018/02496 A ZA2018/02496 A ZA 2018/02496A ZA 201802496 A ZA201802496 A ZA 201802496A ZA 201802496 B ZA201802496 B ZA 201802496B
- Authority
- ZA
- South Africa
- Prior art keywords
- treatment
- jak kinase
- compounds
- kinase inhibitor
- respiratory disease
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- 208000023504 respiratory system disease Diseases 0.000 title abstract 2
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562250113P | 2015-11-03 | 2015-11-03 | |
| PCT/US2016/059999 WO2017079205A1 (en) | 2015-11-03 | 2016-11-02 | Jak kinase inhibitor compounds for treatment of respiratory disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201802496B true ZA201802496B (en) | 2025-01-29 |
Family
ID=57442794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2018/02496A ZA201802496B (en) | 2015-11-03 | 2018-04-16 | Jak kinase inhibitor compounds for treatment of respiratory disease |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US10100049B2 (enExample) |
| EP (1) | EP3371186A1 (enExample) |
| JP (1) | JP6800969B2 (enExample) |
| KR (1) | KR20180073687A (enExample) |
| CN (1) | CN108349972B (enExample) |
| AU (1) | AU2016350816B2 (enExample) |
| BR (1) | BR112018008966B1 (enExample) |
| CA (1) | CA3001542C (enExample) |
| CL (1) | CL2018001145A1 (enExample) |
| CO (1) | CO2018005640A2 (enExample) |
| EA (1) | EA034914B1 (enExample) |
| HK (1) | HK1252685A1 (enExample) |
| IL (1) | IL258772B (enExample) |
| MX (1) | MX374605B (enExample) |
| MY (1) | MY195427A (enExample) |
| NZ (1) | NZ741737A (enExample) |
| PH (1) | PH12018500828B1 (enExample) |
| SA (1) | SA518391470B1 (enExample) |
| TW (1) | TWI710560B (enExample) |
| UA (1) | UA123633C2 (enExample) |
| WO (1) | WO2017079205A1 (enExample) |
| ZA (1) | ZA201802496B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY195427A (en) | 2015-11-03 | 2023-01-20 | Theravance Biopharma R&D Ip Llc | Jak Kinase Inhibitor Compounds for Treatment of Respiratory Disease |
| ES2864035T3 (es) | 2015-11-03 | 2021-10-13 | Topivert Pharma Ltd | Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina y 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inhibidores de la quinasa janus |
| US10556901B2 (en) | 2015-11-03 | 2020-02-11 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors |
| AU2018231032B2 (en) | 2017-03-09 | 2021-08-19 | Theravance Biopharma R&D Ip, Llc | JAK inhibitors containing a 4-membered heterocyclic amide |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| RU2764979C2 (ru) | 2017-05-01 | 2022-01-24 | ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи | Способы лечения с использованием соединения-ингибитора jak |
| WO2018204236A1 (en) * | 2017-05-01 | 2018-11-08 | Theravance Biopharma R&D Ip, Llc | Crystalline forms of a jak inhibitor compound |
| US20200281857A1 (en) | 2017-11-22 | 2020-09-10 | Dauntless 1, Inc. | Therapeutic compound formulations |
| WO2019246273A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor |
| WO2020051135A1 (en) * | 2018-09-04 | 2020-03-12 | Theravance Biopharma R&D Ip, Llc | Process for preparing jak inhibitors and intermediates thereof |
| DK3837258T3 (da) | 2018-09-04 | 2024-07-22 | Theravance Biopharma R&D Ip Llc | Dimethyl amino azetidine amides as jak inhibitors |
| ES2955717T3 (es) | 2018-09-04 | 2023-12-05 | Theravance Biopharma R&D Ip Llc | Amidas heterocíclicas de 5 a 7 elementos como inhibidores de JAK |
| JP2022506111A (ja) * | 2018-10-29 | 2022-01-17 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｊａｋ阻害剤としての２－アザビシクロヘキサン化合物 |
| AU2019384733A1 (en) | 2018-11-19 | 2021-06-24 | New York University | Inhibitors of gli1 as therapeutic agents |
| AU2020228799B2 (en) | 2019-02-25 | 2024-12-05 | Henan Medinno Pharmaceutical Technology Co., Ltd. | JAK inhibitor compound and use thereof |
| CN114075200A (zh) * | 2020-08-14 | 2022-02-22 | 河南迈英诺医药科技有限公司 | 用于治疗重症肺炎的jak抑制剂化合物 |
| MA55201A (fr) | 2019-03-05 | 2022-01-12 | Incyte Corp | Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021136345A1 (zh) * | 2019-12-30 | 2021-07-08 | 路良 | Jak抑制剂化合物及其用途 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| TW202144343A (zh) | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶水合物 |
| WO2022178215A1 (en) | 2021-02-19 | 2022-08-25 | Theravance Biopharma R&D Ip, Llc | Amino amide tetrahydro imidazo pyridines as jak inhibitors |
| CN117083273A (zh) | 2021-03-26 | 2023-11-17 | 施万生物制药研发Ip有限责任公司 | Jak抑制剂化合物的二盐酸盐的晶型 |
| TW202317550A (zh) * | 2021-06-25 | 2023-05-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 作為jak抑制劑之咪唑吲唑化合物 |
| CN114181055A (zh) * | 2021-12-21 | 2022-03-15 | 苏州楚凯药业有限公司 | 1-苄氧基-4-溴-5-乙基-2-氟苯的制备方法 |
| JP2025515078A (ja) | 2022-05-05 | 2025-05-13 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | 噴霧経口吸入による送達のためのネズルシチニブ |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| WO2005009389A2 (en) | 2003-07-23 | 2005-02-03 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| CA2673125C (en) | 2006-10-19 | 2015-04-21 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| CA2727036C (en) | 2008-06-20 | 2017-03-21 | Genentech, Inc. | Triazolopyridine jak inhibitor compounds and methods |
| WO2010039825A2 (en) | 2008-10-01 | 2010-04-08 | Array Biopharma Inc. | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS |
| CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
| CA2756989A1 (en) | 2009-04-03 | 2010-10-07 | Douglas Burdi | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| CN106420756A (zh) | 2009-07-28 | 2017-02-22 | 里格尔药品股份有限公司 | 抑制jak途径的组合物和方法 |
| NO3001903T3 (enExample) | 2009-12-21 | 2018-03-24 | ||
| EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| EA024026B1 (ru) | 2010-11-25 | 2016-08-31 | Рациофарм Гмбх | Новые соли и полиморфные формы афатиниба |
| US8575336B2 (en) * | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| TW201513861A (zh) * | 2013-01-17 | 2015-04-16 | Galapagos Nv | 用於治療退化性及發炎疾病之新穎化合物 |
| BR112016012262B1 (pt) | 2013-12-05 | 2021-04-13 | Pfizer Inc | Acrilamidas heterocíclicas farmaceuticamente ativas e composições para tratar e prevenir condições mediadas por jac |
| MD20160121A2 (ro) | 2014-05-14 | 2017-05-31 | Pfizer Inc. | Pirazolopiridine şi pirazolopirimidine |
| WO2016026078A1 (en) | 2014-08-19 | 2016-02-25 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as erk inhibitors |
| KR101663277B1 (ko) | 2015-03-30 | 2016-10-06 | 주식회사 녹십자 | TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물 |
| MY195427A (en) | 2015-11-03 | 2023-01-20 | Theravance Biopharma R&D Ip Llc | Jak Kinase Inhibitor Compounds for Treatment of Respiratory Disease |
| US10556901B2 (en) | 2015-11-03 | 2020-02-11 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors |
| ES2864035T3 (es) | 2015-11-03 | 2021-10-13 | Topivert Pharma Ltd | Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina y 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inhibidores de la quinasa janus |
| AU2018231032B2 (en) | 2017-03-09 | 2021-08-19 | Theravance Biopharma R&D Ip, Llc | JAK inhibitors containing a 4-membered heterocyclic amide |
| RU2764979C2 (ru) | 2017-05-01 | 2022-01-24 | ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи | Способы лечения с использованием соединения-ингибитора jak |
| WO2018204236A1 (en) | 2017-05-01 | 2018-11-08 | Theravance Biopharma R&D Ip, Llc | Crystalline forms of a jak inhibitor compound |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| WO2020051135A1 (en) | 2018-09-04 | 2020-03-12 | Theravance Biopharma R&D Ip, Llc | Process for preparing jak inhibitors and intermediates thereof |
| ES2955717T3 (es) | 2018-09-04 | 2023-12-05 | Theravance Biopharma R&D Ip Llc | Amidas heterocíclicas de 5 a 7 elementos como inhibidores de JAK |
| DK3837258T3 (da) | 2018-09-04 | 2024-07-22 | Theravance Biopharma R&D Ip Llc | Dimethyl amino azetidine amides as jak inhibitors |
| JP2022506111A (ja) | 2018-10-29 | 2022-01-17 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｊａｋ阻害剤としての２－アザビシクロヘキサン化合物 |
| CN117083273A (zh) | 2021-03-26 | 2023-11-17 | 施万生物制药研发Ip有限责任公司 | Jak抑制剂化合物的二盐酸盐的晶型 |
-
2016
- 2016-11-02 MY MYPI2018701385A patent/MY195427A/en unknown
- 2016-11-02 JP JP2018522556A patent/JP6800969B2/ja not_active Expired - Fee Related
- 2016-11-02 UA UAA201806062A patent/UA123633C2/uk unknown
- 2016-11-02 MX MX2018005446A patent/MX374605B/es active IP Right Grant
- 2016-11-02 PH PH1/2018/500828A patent/PH12018500828B1/en unknown
- 2016-11-02 HK HK18111992.5A patent/HK1252685A1/zh unknown
- 2016-11-02 WO PCT/US2016/059999 patent/WO2017079205A1/en not_active Ceased
- 2016-11-02 EP EP16804947.6A patent/EP3371186A1/en not_active Withdrawn
- 2016-11-02 AU AU2016350816A patent/AU2016350816B2/en not_active Ceased
- 2016-11-02 KR KR1020187015680A patent/KR20180073687A/ko not_active Withdrawn
- 2016-11-02 NZ NZ741737A patent/NZ741737A/en unknown
- 2016-11-02 EA EA201891091A patent/EA034914B1/ru unknown
- 2016-11-02 US US15/341,226 patent/US10100049B2/en active Active
- 2016-11-02 CN CN201680063886.1A patent/CN108349972B/zh not_active Expired - Fee Related
- 2016-11-02 CA CA3001542A patent/CA3001542C/en active Active
- 2016-11-02 TW TW105135436A patent/TWI710560B/zh not_active IP Right Cessation
- 2016-11-02 BR BR112018008966-4A patent/BR112018008966B1/pt not_active IP Right Cessation
-
2018
- 2018-04-16 ZA ZA2018/02496A patent/ZA201802496B/en unknown
- 2018-04-17 IL IL258772A patent/IL258772B/en active IP Right Grant
- 2018-04-30 SA SA518391470A patent/SA518391470B1/ar unknown
- 2018-04-30 CL CL2018001145A patent/CL2018001145A1/es unknown
- 2018-05-29 CO CONC2018/0005640A patent/CO2018005640A2/es unknown
- 2018-07-18 US US16/038,424 patent/US10183942B2/en active Active
- 2018-12-10 US US16/215,194 patent/US10526330B2/en active Active
-
2019
- 2019-11-20 US US16/689,706 patent/US10913740B2/en not_active Expired - Fee Related
-
2021
- 2021-01-05 US US17/248,015 patent/US11299492B2/en active Active
-
2022
- 2022-03-07 US US17/688,001 patent/US11718616B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201802496B (en) | Jak kinase inhibitor compounds for treatment of respiratory disease | |
| PH12019501985A1 (en) | Fused imidazo-piperidine jak inhibitors | |
| PH12017502050A1 (en) | Naphthyridine compounds as jak kinase inhibitors | |
| PH12019502264A1 (en) | Fused imidazo-piperidine jak inhibitors compound | |
| ZA202001717B (en) | Compounds, salts thereof and methods for treatment of diseases | |
| SG10201811384TA (en) | Mnk inhibitors and methods related thereto | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| MX375674B (es) | Compuestos de carboxamida inhibidores de la actividad de cinasa rip2. | |
| EA201791576A1 (ru) | Ингибитор jak | |
| MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
| PH12021550368A1 (en) | Dimethyl amino azetidine amides as jak inhibitors | |
| PH12020500528A1 (en) | Pyrimidine compound as jak kinase inhibitor | |
| MX2017006048A (es) | 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetrahidropiridi nas en calidad de inhibidores de bace1 para tratar enfermedad de alzheimer. | |
| MY197440A (en) | Heteroamatic compounds as btk inhibitors | |
| PH12021550324A1 (en) | 5 to 7 membered heterocyclic amides as jak inhibitors | |
| PH12019500497A1 (en) | Heteroaryl carboxamide compounds as inhibitors of ripk2 | |
| EA201692260A1 (ru) | Соединения 1,3,4-тиадиазола и их применение в лечении рака | |
| SA521422152B1 (ar) | Vanin مركبات عطرية غير متجانسة كمثبطات | |
| MX2021006490A (es) | Compuestos heteroaromaticos como inhibidores de vanina. | |
| EA201792265A1 (ru) | Способы лечения сердечно-сосудистых заболеваний | |
| EA202192822A1 (ru) | Нафтиридиновые соединения в качестве ингибиторов jak киназы |